XBIT
XBiotech Inc.
There isn't enough reported data to score XBIT yet.
XBIT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
XBIT's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
XBIT PE Valuation
XBIT has no meaningful PE right now: it lost money over the past year.
XBIT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect XBIT's earnings, revenue and profitability to hold roughly steady.
XBIT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.12 | — |
| Q3 2026 | -$1.42 | -$0.46 |
| Q2 2026 | -$1.47 | -$0.55 |
| Q1 2026 | -$1.31 | -$0.02 |
| Q4 2025 | -$1.49 | -$0.23 |
| Q3 2025 | -$0.96 | +$0.11 |
| Q2 2025 | -$0.92 | +$0.23 |
| Q1 2025 | -$1.29 | -$0.28 |
| Q4 2024 | -$1.26 | -$0.45 |
XBIT lost $1.42 per share over the past year, a bigger loss than the year before.
XBIT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $300K | -93% |
| Q3 2022 | $1.7M | -63% |
| Q2 2022 | $1.5M | -66% |
| Q1 2022 | $500K | -90% |
| Q4 2021 | $4.5M | -15% |
| Q3 2021 | $4.5M | -57% |
| Q2 2021 | $4.5M | -71% |
| Q1 2021 | $4.9M | -62% |
XBIT's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -2721% | -2561 points |
| Q3 2022 | -380% | -298 points |
| Q2 2022 | -790% | -556 points |
| Q1 2022 | -1569% | -1496 points |
| Q4 2021 | -160% | -66 points |
| Q3 2021 | -83% | -38 points |
| Q2 2021 | -234% | -192 points |
| Q1 2021 | -73% | -56 points |
XBIT's operating margin was −2721% last quarter, down 2561 points from the same quarter a year ago, near the bottom of its range since 2020.
XBIT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.5M | -$164K |
| Q2 2026 | -$4.5M | +$1.5M |
| Q1 2026 | -$9M | -$2.2M |
| Q4 2025 | -$23M | -$16.4M |
| Q3 2025 | -$4.4M | +$1.8M |
| Q2 2025 | -$6M | +$6M |
| Q1 2025 | -$6.8M | +$643K |
| Q4 2024 | -$6.6M | -$3.1M |
XBIT has burned cash in almost every quarter: −$41M over the past year, against −$24M the year before.
XBIT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | +0.2% | +51.1K shares |
| 5 years | +0.5% | +146K shares |
| Available history | -16% | -5.7M shares |
XBIT has 30M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
XBIT Net Leverage
XBIT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XBIT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.5 | Neutral |
| Stochastic | 16.4 | Oversold |
XBIT's weekly RSI is 34 (neutral) and its Stochastic is 16 (oversold).
XBIT PE vs Healthcare Sector
| Metric | XBIT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XBIT has no meaningful PE right now: it lost money over the past year.
XBIT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.05 | 4.4% below |
| 20 week MA | $2.17 | 9.7% below |
| 50 week MA | $2.32 | 16% below |
| 100 week MA | $2.69 | 27% below |
| 200 week MA | $4.12 | 52% below |
XBIT is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
XBIT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.2 | $16.7 | -13% |
| 2021 | $16.7 | $11.3 | -32% |
| 2022 | $11.3 | $3.08 | -73% |
| 2023 | $3.08 | $4.00 | +30% |
| 2024 | $4.00 | $3.80 | -5% |
| 2025 | $3.80 | $2.47 | -35% |
| 2026 YTD | $2.47 | $1.96 | -21% |
XBIT has finished lower in five of the last six years. It's down 21% so far in 2026.